Compounded 0.03% Tacrolimus in Cross‐Linked Hyaluronate Improves Ocular Surface Health in Dogs With Evaporative Dry Eye Disease
Veterinary Ophthalmology · 2026
DOI: 10.1111/vop.70251 ↗Kurz gefasst
Fachartikel in der Zeitschrift Veterinary Ophthalmology, 2026. Verfasst von Lionel Sebbag und 4 weiteren Autor:innen. Beteiligte Einrichtung: Koret School of Veterinary Medicine, The Hebrew University of Jerusalem, Rehovot, Israel. Hauptthemen laut MEDLINE: Hyaluronic Acid, Tacrolimus, Dog Diseases, Dry Eye Syndromes. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
To assess the clinical effects of a compounded 0.03% tacrolimus in 0.75% cross‐linked hyaluronic acid (XHA) on tear quantity, quality, and ocular surface health in dogs with evaporative dry eye disease (EDED). Procedures Sixteen client‐owned dogs diagnosed with EDED (normal aqueous production yet reduced stability) were enrolled in this prospective, open‐label clinical trial. Patients were treated with the compounded formulation in affected eyes twice daily for 45 days. Ophthalmic assessments, including Schirmer tear test‐1 (STT‐1), tear film breakup time (TFBUT), punctate fluorescein staining (PFS), lissamine green staining, and conjunctival hyperemia scoring, were performed during designated morning appointments at Day 0, Day 15, and Day 45. Data were analyzed using repeated‐measures ANOVA and post hoc tests.
Results
STT‐1 values increased significantly from 18.7 ± 2.3 mm/min at baseline to 21.7 ± 4.1 mm/min at Day 45 ( p = 0.004). Tear film stability improved markedly, with TFBUT rising from 3.3 ± 0.7 s to 5.2 ± 1.4 s (Day 15) and 8.1 ± 2.4 s (Day 45) ( p < 0.001). Ocular surface health improved, evidenced by PFS scores decreasing from 1.8 ± 0.9 to 0.3 ± 0.4 ( p < 0.001) and lissamine green scores dropping from 1.9 ± 1.1 to 0.1 ± 0.3 ( p < 0.001). Conjunctival hyperemia scores declined significantly by Day 45 ( p = 0.041).
Conclusions
Twice‐daily administration of compounded XHA/tacrolimus resulted in significant improvements in tear quantity, stability, and corneoconjunctival integrity. Combining immunomodulation with long‐acting lubrication in a single formulation offers a promising, practical therapeutic strategy for efficiently managing canine qualitative dry eye disease in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Koret School of Veterinary Medicine, The Hebrew University of Jerusalem, Rehovot, Israel.
- School of Veterinary Medicine and Zootechny, Federal University of Bahia, UFBA, Salvador, Brazil.
- Council for Scientific and Technological Development-CNPq, Brasilia, Brazil.
ORCID-Profile: Lionel Sebbag, Eunice Q A Neta, Ana Cláudia S Raposo, Arianne P Oriá
Zitieren
APA
Sebbag, L., Neta, E. Q. A., de Farias, C. R., Raposo, A. C. S., & Oriá, A. P. (2026). Compounded 0.03% Tacrolimus in Cross‐Linked Hyaluronate Improves Ocular Surface Health in Dogs With Evaporative Dry Eye Disease. Veterinary Ophthalmology. https://doi.org/10.1111/vop.70251
Vancouver
Sebbag L, Neta EQA, de Farias CR, Raposo ACS, Oriá AP. Compounded 0.03% Tacrolimus in Cross‐Linked Hyaluronate Improves Ocular Surface Health in Dogs With Evaporative Dry Eye Disease. Veterinary Ophthalmology. 2026. doi:10.1111/vop.70251
BibTeX
@article{Sebbag2026,
author = {Sebbag, Lionel and Neta, Eunice Q A and de Farias, Catharina R and Raposo, Ana Cláudia S and Oriá, Arianne P},
title = {Compounded 0.03% Tacrolimus in Cross‐Linked Hyaluronate Improves Ocular Surface Health in Dogs With Evaporative Dry Eye Disease},
journal = {Veterinary Ophthalmology},
year = {2026},
doi = {10.1111/vop.70251}
}
EUVIMED